Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Given Average Rating of “Moderate Buy” by Analysts

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has received an average rating of “Moderate Buy” from the seven brokerages that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $19.50.

ENTA has been the subject of several recent research reports. HC Wainwright reissued a “buy” rating and issued a $20.00 price objective on shares of Enanta Pharmaceuticals in a research note on Tuesday, June 23rd. Wall Street Zen cut shares of Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Sunday, May 31st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Friday, July 17th.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Janus Henderson Group PLC grew its position in shares of Enanta Pharmaceuticals by 1.5% in the first quarter. Janus Henderson Group PLC now owns 3,784,055 shares of the biotechnology company’s stock valued at $47,717,000 after purchasing an additional 54,396 shares in the last quarter. BlackRock Inc. purchased a new position in Enanta Pharmaceuticals during the second quarter worth approximately $47,304,000. Farallon Capital Management LLC lifted its position in Enanta Pharmaceuticals by 30.6% during the fourth quarter. Farallon Capital Management LLC now owns 2,772,262 shares of the biotechnology company’s stock worth $43,719,000 after buying an additional 650,000 shares in the last quarter. Krensavage Asset Management LLC boosted its stake in Enanta Pharmaceuticals by 30.8% during the fourth quarter. Krensavage Asset Management LLC now owns 2,766,390 shares of the biotechnology company’s stock worth $43,626,000 after buying an additional 651,946 shares during the last quarter. Finally, Millennium Management LLC boosted its stake in Enanta Pharmaceuticals by 50.2% during the first quarter. Millennium Management LLC now owns 1,346,932 shares of the biotechnology company’s stock worth $7,435,000 after buying an additional 449,945 shares during the last quarter. 94.99% of the stock is owned by hedge funds and other institutional investors.

Enanta Pharmaceuticals Trading Down 0.1%

ENTA stock opened at $13.50 on Thursday. Enanta Pharmaceuticals has a 12-month low of $6.60 and a 12-month high of $17.15. The stock has a market cap of $392.58 million, a price-to-earnings ratio of -5.60 and a beta of 0.98. The business’s 50-day moving average is $13.18 and its 200 day moving average is $13.44.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its earnings results on Monday, August 10th. The biotechnology company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.16). The firm had revenue of $14.36 million for the quarter, compared to analyst estimates of $16.76 million. Enanta Pharmaceuticals had a negative net margin of 96.89% and a negative return on equity of 61.61%. As a group, equities analysts forecast that Enanta Pharmaceuticals will post -1.79 EPS for the current fiscal year.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a biotechnology company headquartered in Watertown, Massachusetts, specializing in the discovery and development of novel, small-molecule drugs targeting viral diseases. Leveraging a proprietary chemistry platform, Enanta has built extensive expertise in designing potent inhibitors of viral proteases and polymerases. The company initially gained recognition through partnerships focused on hepatitis C virus (HCV), where its protease inhibitors formed a key component of ABBVIE’s direct‐acting antiviral regimens.

Building on its HCV experience, Enanta has expanded its pipeline to address respiratory syncytial virus (RSV) and other viral infections.